More Questions than Answers at Gene Editing Summit
By Chloe Poston,
Genes to Genomes
| 12. 09. 2015
[cites CGS' Marcy Darnovsky]
Last week, the National Academies of Science and Engineering joined forces with the Chinese Academy of Science and the Royal Society of the United Kingdom to host an International Summit on Human Gene Editing in Washington, DC. Top scholars in genetics, bioengineering, ethics, and law debated the merits of human gene editing; however consensus was far from achieved. In fact, the repeated reminders of “unknown unknowns” and references to Brave New World left participants wondering how such disparate opinions could be formed into a single set of guidelines from the summit organizing committee.
The final statement from the organizing committee, released at the conclusion of the summit, signified that this gathering would not be the place where final decisions were made. Instead, the committee used the three days of insightful perspectives to develop a framework for how information should be collected. The point of the summit was not to answer the looming questions surrounding human gene editing; rather, it was to determine what questions to ask—and of whom—in order to begin developing recommendations on how to move forward with this technology.
The mix of...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...